Business Context and Reporting Period
AFC Gamma, Inc. filed a Form 8-K dated January 19, 2022, reporting completion of a partial exercise of the underwriters’ over-allotment option related to its previously announced public offering. The filing identifies the issuer as AFC Gamma, Inc.; the request metadata refers to Advanced Flower Capital Inc.
Key Financial and Capital Markets Metrics
- The underwriters were granted an option to purchase up to 450,000 additional shares of common stock.
- On January 14, 2022, the underwriters partially exercised the option for 291,832 shares.
- The company completed the sale of those shares on January 19, 2022.
- Total shares sold in the offering, including the optional shares, were 3,291,832.
- Total gross proceeds were approximately $67.5 million, before underwriting discounts and commissions, a structuring fee, and other offering expenses.
- The filing does not provide net proceeds, revenue, profit, cash flow, margins, debt, or liquidity balances.
Material Changes Versus the Prior Comparable Period
The filing reports a capital-raising transaction rather than operating results. Compared with the originally announced 3,000,000-share offering, the completed offering increased share issuance by 291,832 shares and increased gross proceeds to approximately $67.5 million. The filing does not provide a prior-period operating or financial comparison.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance, operating outlook, management commentary, specific risks, contingencies, or unusual operating items are disclosed. The principal reported event is the partial exercise and settlement of the over-allotment option, which resulted in additional equity issuance and potential dilution to existing shareholders.
Investor Verification Items
- Verify the final net proceeds after underwriting discounts, fees, and offering expenses.
- Verify the use of the offering proceeds and the resulting impact on liquidity and leverage.
- Verify the final shares outstanding and dilution to existing shareholders.
- Review subsequent filings for the offering’s effect on investment activity, earnings, dividends, and balance-sheet metrics.